Clinical trials: Placebo-Pre
ST-segment Elevation Myocardial Infarction
Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before PCI (Percutaneous Coronary Intervention) in Patients with STEMI (ST-segment Elevation Myocardial Infarction)
- Trial name
- NCT02070471
- Testing
- LC28-0126 Dose A, LC28-0126 Dose B, LC28-0126 Dose C
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- LG Life Sciences
Rheumatoid Arthritis
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis.
- Trial name
- NCT00810199
- Testing
- tocilizumab [RoActemra/Actemra], methotrexate
- Where
- 137 sites in United States, Brazil and 18 more
- Volunteers
- 556 people
- Sponsor
- Hoffmann-La Roche
Advanced Gastric Cancer
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.
- Trial name
- GRANITE-1 (NCT00879333)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 122 sites in United States, Argentina and 20 more
- Volunteers
- 656 people
- Sponsor
- Novartis Pharmaceuticals
Stage III Non-small-cell Lung Cancer
A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)
This study is a randomized, double-blind, double-dummy,placebo parallel controlled, multi-centre,phase III clinical trial to evaluate the efficacy and safety of TQB2450 with or without anlotinib compared with placebo as…
- Trial name
- NCT04325763
- Testing
- TQB2450, Anlotinib, TQB2450(blank)
- Where
- 36 sites in China
- Volunteers
- 315 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Coronary Heart Disease (CHD)
Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a…
- Trial name
- VESALIUS-CV (NCT03872401)
- Testing
- Evolocumab
- Where
- 852 sites in United States, Argentina and 31 more
- Volunteers
- 12,301 people
- Sponsor
- Amgen
Postoperative Nausea and Vomiting
Study of APD421 as PONV Treatment (Prior Prophylaxis)
Double-blind, randomised, parallel-group, placebo-controlled, adaptive, seamless, dose-selecting study to compare the efficacy of APD421 to placebo as treatment of established PONV, in patients who have had prior PONV prophylaxis.
- Trial name
- NCT02646566
- Testing
- APD421
- Where
- 8 sites in United States, France and 1 more
- Volunteers
- 705 people
- Sponsor
- Acacia Pharma Ltd
Insulin Resistance, Abdominal Obesity
Pilot Study With GFT505 (80mg) in Patients With Insulin Resistance and Abdominal Obesity
The purpose of this study is to demonstrate the efficacy on insulin sensitivity of GFT505 at 80mg/d in male patients with insulin resistance and abdominal obesity. Evaluation will be made using a glucose clamp technique.
- Trial name
- NCT01271777
- Testing
- GFT505 80mg
- Where
- 2 sites in France
- Volunteers
- 22 people
- Sponsor
- Genfit
Anemia, Chronic Kidney Disease
Safety of Single Doses of Peginesatide in Patients With Chronic Kidney Disease
To evaluate the safety profile of single intravenous (IV) dose levels of peginesatide in participants with chronic kidney disease(CKD) not on dialysis.
- Conditions
- Anemia, Chronic Kidney Disease, Chronic Renal Failure
- Trial name
- NCT00109291
- Testing
- peginesatide
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Affymax
Multiple Myeloma Bone Disease
A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients
This study has two portions, a phase I portion and a phase II portion. The purpose of the phase I portion is to assess the maximum-tolerated dose (MTD) and to characterize dose limiting toxicity (DLT) of escalating doses of…
- Trial name
- NCT00741377
- Testing
- BHQ880, Zoledronic acid
- Where
- 9 sites in United States, United Kingdom
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Uterine Myomas
PGL4001 Versus Placebo in Uterine Myomas
This trial will assess the efficacy and safety of PGL4001 with concomitant iron administration versus placebo with concomitant iron administration, over a 3-month period for the pre-operative treatment of pre-menopausal women…
- Trial name
- PEARLI (NCT00755755)
- Testing
- PGL4001 (ulipristal) and iron
- Where
- 38 sites in Czechia, Hungary and 4 more
- Volunteers
- 241 people
- Sponsor
- PregLem SA
Seasonal Allergic Rhinitis
A Study of Tolerability and Safety of a New Cumulative Dose of Grass MATA MPL
There is increasing evidence that the effectiveness of allergy immunotherapy to control symptoms of rhinoconjunctivitis is related to the cumulative dose of allergen or allergoid administered during a single regimen of…
- Trial name
- G104 (NCT03931993)
- Testing
- Grass MATA MPL
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Allergy Therapeutics
Hyperlipidemia
Efficacy, Safety, Tolerability And Actual Use Study Of Bococizumab And An Autoinjector (Pre-Filled Pen) In Subjects With Hyperlipidemia Or Dyslipidemia
This study is a multicenter, randomized study in subjects with high cholesterol receiving statins to assess the efficacy to lower LDL-C, the safety, tolerability and actual use of bococizumab and an autoinjector (pre-filled pen).
- Trial name
- SPIRE-AI (NCT02458287)
- Testing
- Bococizumab 150mg, Bococizumab 75mg
- Where
- 30 sites in United States
- Volunteers
- 299 people
- Sponsor
- Pfizer
Immunocompromised
A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults
The primary objective of the study is to evaluate the effect of casirivimab+imdevimab, compared with placebo, in preventing symptomatic SARS-CoV-2 infection in immunocompromised participants.
- Trial name
- NCT05074433
- Testing
- casirivimab+imdevimab
- Where
- 67 sites in United States, Mexico
- Volunteers
- 66 people
- Sponsor
- Regeneron Pharmaceuticals
Non-Small Cell Lung Cancer
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens.
- Trial name
- NCT00085826
- Testing
- Exisulind
- Where
- 114 sites in United States
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Inc
Uterine Fibroids
Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
Two (2) dose levels of Proellex or placebo will be administered once-daily for up to 91 days. Following screening and a pre-treatment endometrial biopsy, subjects will be followed monthly for the three month treatment phase.
- Trial name
- NCT00882258
- Testing
- 12.5 mg Proellex, 25 mg Proellex
- Where
- 16 sites in United States
- Volunteers
- 144 people
- Sponsor
- Repros Therapeutics Inc.
Dermatitis Atopic
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm study for treatment of participants diagnosed with moderate-to-severe AD on background TCS who have had inadequate…
- Trial name
- AQUA (NCT06241118)
- Testing
- Amlitelimab, Topical corticosteroids, Topical tacrolimus or pimecrolimus
- Where
- 154 sites in United States, Argentina and 20 more
- Volunteers
- 464 people
- Sponsor
- Sanofi
HIV, Premature Aging
Clinical Trial to Evaluate the Addition to an Antiretroviral Treatment of a Probiotic
The main purpose of this study is to evaluate a therapy for the inflammaging (premature aging).
- Trial name
- RECOVER (NCT03542786)
- Testing
- Probiotic, Prebiotic
- Where
- Spain
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- AB Biotics, SA
Locally Advanced or Metastatic Breast Cancer
GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer
GB491-004 is a multicenter, randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of GB491 in combination with fulvestrant in patients with HR-positive, HER2-negative locally advanced or…
- Trial name
- NCT05054751
- Testing
- GB491+ Fulvestrant
- Where
- 54 sites in China
- Volunteers
- 275 people
- Sponsor
- Genor Biopharma Co., Ltd.
Type 2 Diabetes Mellitus, Impaired Glucose Tolerance
To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
This was a 10-week, placebo-controlled, randomized study to investigate the effect of injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or Type 2 Diabetes Mellitus (T2DM) already treated…
- Trial name
- NCT01068860
- Testing
- Canakinumab 150 mg
- Where
- 52 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Novartis
Diarrhea, HIV Infections
A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.
The primary objective of this study is to determine the relapse rate in patients with AIDS-related diarrhea who were found to be "Responders" in a previous placebo-controlled, double-blind study of Sandostatin (Study #D203 - FDA…
- Trial name
- NCT00002253
- Testing
- Octreotide
- Where
- 22 sites in United States
- Sponsor
- Sandoz